Metavia INC 8-K filings

NeuroBo Pharmaceuticals has appointed Marshall Woodworth as its Chief Financial Officer, effective March 1, 2024, after he served as acting CFO since October 2023.

NeuroBo Pharmaceuticals has received its first Institutional Review Board (IRB) approval to begin a Phase 1 clinical trial for its obesity treatment candidate, DA-1726.

NeuroBo Pharmaceuticals has released an updated corporate presentation highlighting its pipeline of treatments for MASH and obesity, along with upcoming clinical milestones.

NeuroBo Pharmaceuticals has received FDA clearance for its Investigational New Drug application for DA-1726, a dual-acting drug for obesity, and plans to begin a Phase 1 clinical trial in the first half of 2024.

NeuroBo Pharmaceuticals reports positive pre-clinical safety data for DA-1241 in combination with sitagliptin and has opened enrollment for Part 2 of its Phase 2a clinical trial for MASH.